Beyond multidrug-resistant tuberculosis in Europe: A TBNET study

G. Günther, F. Van Leth, N. Altet, M. Dedicoat, R. Duarte, G. Gualano, H. Kunst, I. Muylle, V. Spinu, S. Tiberi, P. Viiklepp, C. Lange

Research output: Contribution to journalArticle


The emergence of drug-resistant tuberculosis (TB) is a challenge to TB control in Europe.We evaluated secondline drug susceptibility testing in Mycobacterium tuberculosis isolates from patients with multidrugresistant, pre-extensively drug-resistant (pre-XDR-TB) and XDR-TB at 23 TBNET sites in 16 European countries. Over 30% of bacilli from patients with pre-XDR-TB showed resistance to any fluoroquinolone and almost 70% to any second-line injectable drug. Respectively >90% and >80% of the XDR-TB strains tested showed phenotypic resistance to pyrazinamide and ethambutol. Resistance to prothionamide/ethionamide was high in bacilli from pre-XDR-TB patients (43%) and XDR-TB patients (49%).

Original languageEnglish
Pages (from-to)1524-1527
Number of pages4
JournalInternational Journal of Tuberculosis and Lung Disease
Issue number12
Publication statusPublished - Dec 1 2015


  • Drug resistance
  • Europe
  • Extensively drug-resistant tuberculosis
  • MDR-TB
  • TB
  • Tuberculosis Network European Trials

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Beyond multidrug-resistant tuberculosis in Europe: A TBNET study'. Together they form a unique fingerprint.

Cite this